Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The dividend yield on the S&P 500 is currently around 1.2%, which is near its all-time low. As a result, it's getting harder ...

This data center builder appears undervalued based on its construction pipeline and recent lease agreements made with ...

The upswing has been broad-based across Asia. Four of the world's five largest share-sale venues are in the continent, with ...

AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

Backed by balance sheet clean-ups, execution revivals and sectoral tailwinds, these are the “power performers” that could ...

If earnings stabilise and domestic liquidity stays healthy, 2026 still has room to surprise on the upside for the market, ...

Investors chasing artificial intelligence returns have crowded into the obvious chip leaders, but the biggest percentage ...

Hong Kong and India lead Asia's fundraising surge, with record IPOs and robust market activity amid rising investor ...

If you are wondering whether Ascentage Pharma Group International is still a smart bet after its big run, you are not alone, and this piece is going to dig into what the current price really implies.

UTF keeps a focus on utilities and leveraged yield; results reflect rates and a 7% discount, not portfolio weakness or NAV ...

Explore the complexities of Indian IPOs since 2021, highlighting trends, risks, and the shift from investment to short-term ...